PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

盘后交易 11-27 17:26:54 EST

21.01

+0.10

+0.48%

盘后21.01

+0.000.00%

16:41 EST

最高21.98	最低19.65	成交量174.86万
今开21.76	昨收20.91	日振幅11.15%
总市值19.55亿	流通市值18.66亿	总股本9,306万
成交额3,601万	换手率1.97%	流通股本8,881万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":21.01,"timestamp":1732741200000,"preClose":20.91,"halted":0,"volume":1748649,"hourTrading":{"tag":"盘后","latestPrice":21.01,"preClose":21.01,"latestTime":"16:41 EST","volume":96413,"amount":2025637.9013039998,"timestamp":1732743699873},"delay":0,"floatShares":88806166,"shares":93058132,"eps":-0.894396,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.1,"latestTime":"11-27 17:26:54 EST","open":21.76,"high":21.9823,"low":19.65,"amount":36009122.729811,"amplitude":0.11154,"askPrice":23.12,"askSize":100,"bidPrice":18.41,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.894396,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732755600000},"adr":0,"listingDate":1554955200000,"adjPreClose":20.91,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":22.46,"preClose":20.91,"latestTime":"09:29 EST","volume":5562,"amount":117440.623278,"timestamp":1732717787484},"postHourTrading":{"tag":"盘后","latestPrice":21.01,"preClose":21.01,"latestTime":"16:41 EST","volume":96413,"amount":2025637.9013039998,"timestamp":1732743699873},"volumeRatio":1.465911,"impliedVol":0.4518,"impliedVolPercentile":0.3557},"requestUrl":"/m/hq/s/PD","defaultTab":"news","newsList":[{"id":"2486820656","title":"Pagerduty, Inc.盘中异动 早盘急速拉升5.13%报21.98美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486820656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486820656?lang=zh_cn&edition=full","pubTime":"2024-11-27 22:30","pubTimestamp":1732717832,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日22时30分，Pagerduty, Inc.股票出现异动，股价急速拉升5.13%。截至发稿，该股报21.98美元/股，成交量4.5546万股，换手率0.05%，振幅0.62%。Pagerduty, Inc.股票所在的软件服务行业中，整体涨幅为0.00%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。该公司的产品包括PagerDuty事故管理、DevOps、AIOPs、流程自动化和客户服务运营。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223032971a8d9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127223032971a8d9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","LU1169589451.USD","LU1169590202.USD","PD"],"gpt_icon":0},{"id":"2486891187","title":"刚刚！正大天晴 PD-L1 “贝莫苏拜单抗”获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2486891187","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486891187?lang=zh_cn&edition=full","pubTime":"2024-11-27 12:14","pubTimestamp":1732680840,"startTime":"0","endTime":"0","summary":"截图来源：企业官微贝莫苏拜单抗 是正大天晴自主研发的一款全新序列的创新人源化 PD-L1 单克隆抗体。2022 年 4 月，贝莫苏拜单抗子宫内膜癌适应症曾被 CDE 纳入突破性治疗。此次贝莫苏拜单抗新适应症的获批，将为复发性或转移性子宫内膜癌后线治疗提供新选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-27/doc-incxnmtq6892463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1169589451.USD","BK4023","LU1169590202.USD","PD"],"gpt_icon":0},{"id":"2486783054","title":"PagerDuty Inc 报告截至 10 月 31 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2486783054","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486783054?lang=zh_cn&edition=full","pubTime":"2024-11-27 06:02","pubTimestamp":1732658565,"startTime":"0","endTime":"0","summary":"PagerDuty Inc 报告截至 10 月 31 日的季度业绩 - 收益摘要PagerDuty Inc PD.N 公布的截至 10 月 31 日的季度调整后每股收益为 25 美分，高于去年同期的每股收益 21 美分。13位分析师对该季度的平均预期为每股收益17美分。华尔街预期为每股收益 16 美分至 19 美分。PagerDuty Inc公布的本季度每股收益为亏损7美分。该公司当季亏损 656 万美元。PagerDuty Inc 本季度股价上涨了 11.3%，今年迄今为止亏损了 10.8%。华尔街对 PagerDuty 公司 12 个月目标价的中位数为 21.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241126:nL3S3MX1SL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1169590202.USD","PD","LU1169589451.USD"],"gpt_icon":0},{"id":"2486708965","title":"先为达生物GLP-1新药申报上市，康方生物、正大天晴抗PD-1单抗新适应症申报上市，强生古塞奇尤单抗新给药方式获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486708965","media":"医药经济报","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486708965?lang=zh_cn&edition=full","pubTime":"2024-11-25 20:59","pubTimestamp":1732539575,"startTime":"0","endTime":"0","summary":"先为达生物GLP-1新药申报上市近日，先为达生物开发的偏向型GLP-1受体激动剂新药——伊诺格鲁肽注射液的上市许可申请获中国国家药品监督管理局受理，用于成人2型糖尿病患者血糖控制适应症。正大天晴彼时新闻稿表示，将就该联合疗法的新适应症向CDE递交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125210622a254650e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125210622a254650e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0795875169.SGD","LU1074936037.SGD","IE00BJJMRZ35.SGD","GLP","LU1169589451.USD","LU1244550494.USD","BK4581","LU2089984988.USD","LU0795875086.SGD","LU1032955483.USD","LU0320765646.SGD","BK4023","LU1929549753.HKD","LU1221951046.USD","BK4144","IE00B4R5TH58.HKD","LU1023059063.AUD","IE0002270589.USD","LU0122379950.USD","IE00B1BXHZ80.USD","IE00BVYPNV92.GBP","LU1430594728.SGD","JNJ","BK4585","LU0203347892.USD","LU1162221912.USD","BK4590","LU0912757837.SGD","IE00BFTCPJ56.SGD","LU0234570918.USD","LU0345770308.USD","PD","LU2602419157.SGD","LU0640476718.USD","IE000M9KFDE8.USD","IE0009355771.USD","IE00B3PB1722.GBP","LU2468319806.SGD","IE00BVYPNW00.USD","LU0098860793.USD","LU0203345920.USD","LU1732799900.SGD","LU1732800096.USD","LU2347655156.SGD","IE00BJT1NW94.SGD","LU0234572021.USD","IE00B2B36J28.USD","LU1057294990.SGD","LU1267930813.SGD","IE0002141913.USD"],"gpt_icon":0},{"id":"2486089135","title":"PD-1王炸搭档迎来重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2486089135","media":"瞪羚社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486089135?lang=zh_cn&edition=full","pubTime":"2024-11-25 20:04","pubTimestamp":1732536240,"startTime":"0","endTime":"0","summary":"近日，Replimune Group宣布向FDA提交溶瘤病毒疗法RP1治疗晚期黑色素瘤的生物制品许可申请，本次BLA申请通过加速批准通道提交，同时公司宣布了FDA授予RP1联用O药在同适应症中的突破性疗法认定。另外，RP1可以选择性感染并杀死肿瘤细胞，不会对正常细胞造成严重损害，这也保证了其治疗的安全性。即便是PD-1单药，二线治疗肢端和黏膜黑色素瘤的ORR分别为14-15.8%和0-13.3%。过往已有临床数据初步验证了“溶瘤病毒+PD-1或其他免疫检查点”能够增强对于不同肿瘤的疗效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/25200445661532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["PD","BK4023","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2485340411","title":"和誉-B(02256)：口服PD-L1小分子抑制剂ABSK043联合FGFR2/3小分子抑制剂ABSK061治疗实体瘤的II期临床完成首例胃癌患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2485340411","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485340411?lang=zh_cn&edition=full","pubTime":"2024-11-22 12:25","pubTimestamp":1732249557,"startTime":"0","endTime":"0","summary":"剂量递增将评估ABSK061及ABSK043在FGFR2/3激活改变或过表达的转移性/不可切除的晚期实体瘤患者中的安全性、耐受性、初步疗效和PK特征，并推荐用于扩展期的给药剂量。ABSK043为一款全新的具备优异活性及高度选择性的口服小分子PD-L1抑制剂。截至目前，全球已有多款PD-1/PD-L1单抗药物获批上市，但并无PD-1/PD-L1口服小分子药物获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4023","LU1169589451.USD","LU2488822045.USD","LU1169590202.USD","PD","02256"],"gpt_icon":0},{"id":"2485483721","title":"港股异动 | 康方生物(09926)早盘涨超5% 和正大天晴抗PD-1单抗新适应症申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2485483721","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485483721?lang=zh_cn&edition=full","pubTime":"2024-11-21 10:21","pubTimestamp":1732155662,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物早盘涨超5%，截至发稿，涨5.05%，报73.9港元，成交额2.8亿港元。消息面上，11月21日，中国国家药监局药品审评中心官网公示，康方生物和正大天晴在研的抗PD-1抗体派安普利单抗注射液，以及正大天晴在研的盐酸安罗替尼胶囊上市申请获得受理。据悉，派安普利单抗是一款新型差异化抗PD-1单抗，该产品由康方生物研发，并由康方生物与正大天晴合资的正大天晴康方负责后续开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","LU0348783233.USD","IE00B5MMRT66.SGD","LU0348784397.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU1720050803.USD","LU2488822045.USD","PD","BK1574","BK1161","LU1169589451.USD","BK4023","09926","LU1169590202.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2485310493","title":"康方生物(09926)和正大天晴抗PD-1单抗新适应症申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2485310493","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485310493?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:15","pubTimestamp":1732151710,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月21日，中国国家药监局药品审评中心官网公示，康方生物和正大天晴在研的抗PD-1抗体派安普利单抗注射液，以及正大天晴在研的盐酸安罗替尼胶囊上市申请获得受理。正大天晴彼时新闻稿表示，将就该联合疗法的新适应症向CDE递交上市申请。在2024年ESMO年会上，安罗替尼联合派安普利单抗一线治疗晚期肝细胞癌的3期临床研究成果首次亮相。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1213813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1794554557.SGD","IE00BPRC5H50.USD","LU2488822045.USD","LU1169589451.USD","BK1161","IE00B5MMRT66.SGD","LU0348784397.USD","PD","BK4023","IE00B543WZ88.USD","LU0417516571.SGD","LU0348783233.USD","LU1720050803.USD","09926","LU1169590202.USD","BK1574"],"gpt_icon":0},{"id":"2483565108","title":"近33亿美元！默沙东“牵手”礼新医药，PD-(L)1/VEGF领域交易频发","url":"https://stock-news.laohu8.com/highlight/detail?id=2483565108","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483565108?lang=zh_cn&edition=full","pubTime":"2024-11-16 12:32","pubTimestamp":1731731534,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明上海报道连日来，PD-（L）1/VEGF双特异性抗体领域迎来多起重磅交易。14日晚间，默沙东宣布已协议获得礼新医药新型在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可。根据协议条款，礼新医药将获得5.88亿美元的首付款及最高27亿美元的里程碑付款。该交易预计将于2024年第四季度完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411163241601423.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411163241601423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE0002141913.USD","LU1061106388.HKD","SG9999015341.SGD","IE00BFTCPJ56.SGD","LU0106261372.USD","IE00B2B36J28.USD","LU1941712264.USD","BK4023","LU0208291251.USD","LU2361045086.USD","LU0861579265.USD","BK1515","IE00BN8TJ469.HKD","SG9999014575.USD","LU0058720904.USD","MRK","SG9999001176.SGD","LU0203347892.USD","BK4007","LU1116320737.USD","LU0965509101.SGD","BK4585","IE0009355771.USD","LU1941712348.USD","LU1983299246.USD","LU2324357040.USD","PD","LU2461242641.AUD","LU0203345920.USD","LU1917777945.USD","IE000M9KFDE8.USD","LU1066051225.USD","BK4559","LU1169590202.USD","LU1169589451.USD","SG9999013999.USD","LU2089984988.USD","09939","LU1093756168.USD","LU2106854487.HKD","IE00BBT3K403.USD","L","LU0211331839.USD","LU0985320562.USD","SG9999015358.SGD","LU1037948541.HKD","LU2023250843.SGD","LU0234572021.USD","LU0965509010.AUD","LU0965508806.USD"],"gpt_icon":0},{"id":"2483738558","title":"多种模式并驾齐驱 创新药出海捷报频传","url":"https://stock-news.laohu8.com/highlight/detail?id=2483738558","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483738558?lang=zh_cn&edition=full","pubTime":"2024-11-16 08:29","pubTimestamp":1731716986,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0203345920.USD","PD","LU0289739699.SGD","09939","06978","LU0265550946.USD","LU1064130708.USD","LU2112291526.USD","BK1161","LU0070302665.USD","159992","SG9999001440.SGD","BK1574","LU1066053197.SGD","399441","LU0266013472.USD","LU1291159041.SGD","02162","LU1066051225.USD","BK4550","IE00BJT1NW94.SGD","LU2361044865.SGD","LU1169589451.USD","LU0208291251.USD","LU1093756325.SGD","BK1583","BK4534","LU1061106388.HKD","LU2023250504.SGD","LU0985320562.USD","LU2089984988.USD","159938","SG9999002224.SGD","LU2106854487.HKD","SG9999014575.USD","BK0060","BK0196","161726","LU1917777945.USD","IE00BN8TJ469.HKD","BK0188","600276","LU1989772840.SGD","MRK","LU1057294990.SGD","LU1983299246.USD","SG9999002232.USD","LU1169590202.USD","SG9999014559.SGD"],"gpt_icon":0},{"id":"2483439413","title":"默沙东花超200亿元引进礼新医药PD-1双抗，南京蓬勃将获分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2483439413","media":"中新经纬","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483439413?lang=zh_cn&edition=full","pubTime":"2024-11-15 15:51","pubTimestamp":1731657063,"startTime":"0","endTime":"0","summary":"交易对价超200亿元据默沙东中国，礼新医药将获得5.88亿美元的首付款。2024年二季度报显示，默沙东在肿瘤领域的研发管线包括多款ADC产品，MK-1022、MK-2870、MK-2400等，以及PD-1与其他药物的双免方案开发，例如LAG-3抗体MK-4280、抗CTLA-4抗体MK-1308等。15日早间，金斯瑞生物科技发布公告称，该公司获悉，默沙东与礼新医药已订立独家全球许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115155335a23a3cb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115155335a23a3cb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4534","LU0320765489.SGD","LU0203347892.USD","LU1917777945.USD","LU0965509010.AUD","SG9999015358.SGD","LU1169589451.USD","PD","LU1061106388.HKD","LU1023059063.AUD","LU2106854487.HKD","LU1974910355.USD","LU1093756168.USD","IE00BLSP4239.USD","LU2361045086.USD","MRK","LU0965509283.SGD","SG9999001176.USD","SGXZ57979304.SGD","LU2112291526.USD","LU1066051811.HKD","BK4516","LU1989772840.SGD","IE000M9KFDE8.USD","LU1116320901.HKD","SG9999014542.SGD","IE0002141913.USD","LU0070302665.USD","LU0203345920.USD","BK4559","LU0238689110.USD","LU1057294990.SGD","LU2324357040.USD","SG9999001440.SGD","LU2461242641.AUD","LU2361044949.HKD","IE00B2B36J28.USD","LU0265550359.USD","IE00BFTCPJ56.SGD","LU0006306889.USD","LU1116320737.USD","IE00B1BXHZ80.USD","LU2361044865.SGD","LU1934455277.USD","LU1169590202.USD","LU1037948897.HKD","LU0058720904.USD","LU0265550946.USD","LU0122379950.USD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2483879631","title":"默沙东：协议获得礼新医药在研PD-1/VEGF双特异性抗体LM-299全球独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2483879631","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483879631?lang=zh_cn&edition=full","pubTime":"2024-11-14 20:13","pubTimestamp":1731586425,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["SG9999014559.SGD","LU0106261372.USD","09939","BK4007","LU1941712264.USD","LU1989771016.USD","LU0266013472.USD","PD","BK4559","LU1291159041.SGD","LU0289739699.SGD","LU2361045086.USD","LU1066051225.USD","LU1116320737.USD","IE00BLSP4239.USD","MRK","LU1934455863.HKD","SG9999001440.SGD","LU1934455277.USD","LU1917777945.USD","IE0009355771.USD","LU1093756168.USD","LU1169590202.USD","SG9999014567.USD","LU0265550946.USD","SG9999014542.SGD","SG9999001176.USD","LU0203345920.USD","IE00B1BXHZ80.USD","LU1989772840.SGD","LU2106854487.HKD","LU1057294990.SGD","LU0965509010.AUD","SG9999013999.USD","LU1430594728.SGD","LU0203347892.USD","LU0265550359.USD","LU1983299246.USD","LU2023250843.SGD","SG9999015341.SGD","159938","LU0238689110.USD","LU1585245621.USD","SG9999002224.SGD","SG9999002232.USD","SGXZ57979304.SGD","IE000M9KFDE8.USD","LU1066051498.USD","BK1161","BK4023"],"gpt_icon":0},{"id":"2482083706","title":"百济神州单季营收首超10亿美元 三季度PD-1销售额超11亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482083706","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482083706?lang=zh_cn&edition=full","pubTime":"2024-11-12 22:32","pubTimestamp":1731421971,"startTime":"0","endTime":"0","summary":"百济神州今年前三季度收入已超去年全年，两大核心肿瘤药单季度商业化表现亮眼。11月12日晚间，百济神州（BGNE.NS；06160.HK；688235.SH）发布2024年三季报。前三季度营业收入191.36亿元，同比增长48.63%，其中前三季度产品收入189.86亿元，同比增长72.9%。2023年，百济神州营业收入174.23亿元，其中产品收入155.04亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411123237424693.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411123237424693.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","BGNE","PD"],"gpt_icon":0},{"id":"2482671170","title":"天演药业于2024 SITC年会上公布其抗 CTLA-4 SAFEbody® ADG126（Muzastotug）单一疗法及与抗 PD-1 疗法联用最新临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2482671170","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482671170?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:07","pubTimestamp":1731377220,"startTime":"0","endTime":"0","summary":"公司以海报形式介绍其抗 CTLA-4 SAFEbody ADG126作为单一疗法和与抗 PD-1 疗法联合治疗的最新临床数据，进一步验证其显著提高了治疗指数。数据彰显了ADG126 具备抗 CTLA-4 药物同类最佳潜力，也是继续评估其作为潜在基石疗法与其他药物联用的有力支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4553959_ZH53959_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","LU1169589451.USD","ADAG","BK4023","SITC","PD","BK4080","BK4231","LU1169590202.USD"],"gpt_icon":0},{"id":"2481299001","title":"君实生物(01877)抗PD-1单抗鼻咽癌2期研究数据发表 患者客观缓解率达61.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481299001","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481299001?lang=zh_cn&edition=full","pubTime":"2024-11-07 10:31","pubTimestamp":1730946703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月6日，君实生物宣布，针对顺铂不耐受的复发/转移性鼻咽癌患者的临床研究——特瑞普利单抗联合吉西他滨一线治疗顺铂不耐受的R/M NPC的2期研究最新数据在国际期刊《细胞报告医学》上发表。以特瑞普利单抗为代表的抗PD-1单抗联合吉西他滨+顺铂方案已成为R/M NPC患者的一线标准治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1207816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","BK1515","BK0239","688180","BK1161","LU1169590202.USD","BK4023","BK1583","PD","01877"],"gpt_icon":0},{"id":"2481398515","title":"Pagerduty, Inc.盘中异动 股价大涨5.27%报19.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481398515","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481398515?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:31","pubTimestamp":1730903507,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时31分，Pagerduty, Inc.股票出现波动，股价大幅拉升5.27%。截至发稿，该股报19.97美元/股，成交量7.1365万股，换手率0.08%，振幅1.08%。Pagerduty, Inc.股票所在的软件服务行业中，整体涨幅为1.09%。Pagerduty, Inc.公司简介：PagerDuty 是一个数字运营管理平台，可为现代数字业务管理紧急和任务关键型工作。该公司的产品包括PagerDuty事故管理、DevOps、AIOPs、流程自动化和客户服务运营。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223147a21d2a3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223147a21d2a3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169590202.USD","LU1169589451.USD","PD","BK4023"],"gpt_icon":0},{"id":"2479035399","title":"基石药业：公司PD-L1舒格利单抗在英国获批 系国产首家","url":"https://stock-news.laohu8.com/highlight/detail?id=2479035399","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479035399?lang=zh_cn&edition=full","pubTime":"2024-10-31 22:05","pubTimestamp":1730383548,"startTime":"0","endTime":"0","summary":"10月31日，基石药业宣布，英国药品和医疗保健用品管理局（MHRA）已批准其PD-L1舒格利单抗联合含铂化疗用于无EGFR敏感突变，或无ALK、ROS1、RET基因组肿瘤变异的转移性非小细胞肺癌（下称：NSCLC）成人患者的一线治疗。这是继欧盟委员会批准之后，舒格利单抗在海外市场获得的第二项上市许可申请的批准，也是首个拿到英国市场“入场券”的国产PD-L1。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202410313225109284.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PD","LU1169590202.USD","LU1169589451.USD","BK4023"],"gpt_icon":0},{"id":"2479973986","title":"礼来：终止一款PD-1激动剂研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2479973986","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479973986?lang=zh_cn&edition=full","pubTime":"2024-10-31 00:02","pubTimestamp":1730304126,"startTime":"0","endTime":"0","summary":"10月30日，礼来发布2024年第三季度财报，前三季度营业收入315亿美元，同比增长27%，净利润61.8亿美元。财报公布后，礼来美股盘前大跌逾10%。此外，在研发管线方面，礼来宣布决定终止一款治疗难治性类风湿关节炎的PD-1激动剂抗体Peresolimab研究，Peresolimab为全球范围内临床进展最快的PD-1激动剂抗体。PD-1抑制剂抗体引领了整个肿瘤免疫领域的突破进展，但PD-1激动剂抗体则在自免适应症的探索中遇到了重大挫折。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031000722a1fb8bcb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241031000722a1fb8bcb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0256863811.USD","LU0689472784.USD","LU0820561818.USD","IE00B2B36J28.USD","LU1035775433.USD","LU0061475181.USD","BK4585","BK4007","LU0354030511.USD","LU0094547139.USD","IE00BJJMRZ35.SGD","LU0109391861.USD","LU0820561909.HKD","BK4581","LU0058720904.USD","LU0256863902.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0354030438.USD","LU0708995401.HKD","LU0122379950.USD","LU0417517546.SGD","LU1093756168.USD","BK4534","LU0385154629.USD","LU0640476718.USD","LU0289739699.SGD","IE0004445239.USD","LU0882574139.USD","IE0002141913.USD","LU0456855351.SGD","LU0097036916.USD","LU1064131342.USD","PD","LU0198837287.USD","LU1023059063.AUD","LU0471298777.SGD","LU0943347566.SGD","LU0203202063.USD","GB00BDT5M118.USD","LU1169589451.USD","LU0882574055.USD","LLY","LU0238689110.USD","LU0203201768.USD","LU1057294990.SGD","LU1069344957.HKD","LU0106261372.USD","IE00BJLML261.HKD","IE00BK4W5L77.USD"],"gpt_icon":1},{"id":"2479825667","title":"美股异动 | 礼来(LLY.US)终止PD-1激动剂候选药物研究 AnaptysBio(ANAB.US)暴跌超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479825667","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479825667?lang=zh_cn&edition=full","pubTime":"2024-10-30 22:26","pubTimestamp":1730298360,"startTime":"0","endTime":"0","summary":"周三，AnaptysBio(ANAB.US)股价走低，截至发稿，该股跌超20%，报24.455美元。AnaptysBio正在推进一种与礼来(LLY.US)PD-1激动剂抗体Peresolimab类似的关节炎疗法，在礼来宣布决定终止对该候选药物的研究后，AnaptysBio股价大跌。今年7月，H.C. Wainwright首次覆盖AnaptysBio，给予“买入”评级和55美元的目标价。该行认为其旗下的PD-1激动剂rosnilimab可能比peresolimab更有效。rosnilimab的试验初步数据预计将在2025年第一季度公布。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"69b555e67b9b57f18da6272607047169","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-30/doc-incukean0821980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LLY","LU0354030511.USD","BK4516","BK4581","LU0640476718.USD","IE0004445239.USD","LU1064131342.USD","IE00BJLML261.HKD","IE00BJT1NW94.SGD","PD","IE00B1BXHZ80.USD","LU0354030438.USD","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","LU1023059063.AUD","LU0417517546.SGD","LU0943347566.SGD","LU0203202063.USD","LU1035775433.USD","IE0002141913.USD","LU0058720904.USD","LU0061475181.USD","GB00BDT5M118.USD","LU0238689110.USD","LU0106261372.USD","LU0094547139.USD","BK4588","LU0198837287.USD","BK4534","LU0320765059.SGD","LU0096364046.USD","IE00B4R5TH58.HKD","BK4533","ANAB","LU1057294990.SGD","IE00B2B36J28.USD","LU0256863902.USD","LU0456855351.SGD","LU0820561818.USD","LU0823416689.USD","BK4585","LU0079474960.USD","LU0882574139.USD","LU0672654240.SGD","BK4023","IE00BFTCPJ56.SGD","BK4139","LU0006306889.USD","LU0114720955.EUR","LU0471298694.HKD"],"gpt_icon":0},{"id":"2479229269","title":"PD-1单抗大适应证销售放量，君实生物业绩减亏三成","url":"https://stock-news.laohu8.com/highlight/detail?id=2479229269","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479229269?lang=zh_cn&edition=full","pubTime":"2024-10-30 09:37","pubTimestamp":1730252266,"startTime":"0","endTime":"0","summary":"10月29日晚间，君实生物（01877.HK、688180.SH）发布的三季报显示，今年前三季度，公司归属上市公司股东的净亏损收窄至9.27亿元，相比去年同期减亏4.8亿元，即减亏34.12%。业绩减亏背后，一是源于君实生物商业化药品销售收入的增长；二是公司也将资源聚焦于更具潜力的研发项目，临床、技术服务费及职工薪酬相应减少。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202410303222523725.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202410303222523725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4023","BK1515","LU1169590202.USD","LU1169589451.USD","BK1161","BK1583","PD","01877"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":0.1188},{"period":"1month","weight":0.1643},{"period":"3month","weight":0.0745},{"period":"6month","weight":0.1649},{"period":"1year","weight":-0.0292},{"period":"ytd","weight":-0.0968}],"compareEarnings":[{"period":"1week","weight":0.0175},{"period":"1month","weight":0.0373},{"period":"3month","weight":0.0759},{"period":"6month","weight":0.1493},{"period":"1year","weight":0.3216},{"period":"ytd","weight":0.2637}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律注册成立。PagerDuty是数字企业的中枢神经系统。PagerDuty利用几乎任何支持软件的系统或设备的数字信号，将其与人工响应数据相结合，并协调团队实时采取正确的行动。公司的产品可帮助组织改善运营，加速创新，增加收入，降低安全风险并提供出色的客户体验。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.052063},{"month":2,"riseRate":0.6,"avgChangeRate":-0.030334},{"month":3,"riseRate":0.4,"avgChangeRate":-0.028164},{"month":4,"riseRate":0.4,"avgChangeRate":-0.029577},{"month":5,"riseRate":0.333333,"avgChangeRate":0.0049},{"month":6,"riseRate":0.666667,"avgChangeRate":0.013501},{"month":7,"riseRate":0.5,"avgChangeRate":0.011648},{"month":8,"riseRate":0.5,"avgChangeRate":-0.00702},{"month":9,"riseRate":0,"avgChangeRate":-0.131039},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.037852},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063779},{"month":12,"riseRate":0.6,"avgChangeRate":0.069164}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}